Torrent Pharmaceuticals · NSE: TORNTPHARM · BSE: 500420
Q4 FY26 results · Jan–Mar 2026
Torrent Pharmaceuticals reported revenue from operations of ₹4,197.00 crore (up 41.8% from Q4 FY25) and net profit of ₹364.00 crore (down 26.9% from Q4 FY25) for Q4 FY26 (Jan–Mar 2026), on a consolidated basis.
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 4,197.00 | 2,959.00 | +41.8% | 3,303.00 | +27.1% |
| Other income | (17.00) | (18.00) | Loss narrowed | (13.00) | Loss widened |
| Total income | 4,180.00 | 2,941.00 | +42.1% | 3,290.00 | +27.1% |
| Profit before tax | 529.00 | 665.00 | −20.5% | 814.00 | −35.0% |
| Net profit for the period | 364.00 | 498.00 | −26.9% | 635.00 | −42.7% |
| Attributable to shareholders of the company | 389.00 | 498.00 | −21.9% | 635.00 | −38.7% |
| EPS, basic (₹) | 11.51 | 14.71 | −21.8% | 18.77 | −38.7% |
| Net margin (%) | 8.7 | 16.8 | 19.2 |
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,735.00 | 2,433.00 | +12.4% | 2,599.00 | +5.2% |
| Other income | 58.00 | 15.00 | +286.7% | (8.00) | Turned profit |
| Total income | 2,793.00 | 2,448.00 | +14.1% | 2,591.00 | +7.8% |
| Profit before tax | 592.00 | 622.00 | −4.8% | 757.00 | −21.8% |
| Net profit for the period | 467.00 | 474.00 | −1.5% | 577.00 | −19.1% |
| EPS, basic (₹) | 13.80 | 14.00 | −1.4% | 17.04 | −19.0% |
| Net margin (%) | 17.1 | 19.5 | 22.2 |
Consolidated
- Filed with BSE
- 23 May 2026, 12:01 IST
- Board meeting
- 22 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 23 May 2026, 12:01 IST
- Board meeting
- 22 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Audited
- Source
- XBRL filing on BSE